With zero reported cases of severe side effects like CRS or ICANS, Allogene's therapy can be administered in an outpatient setting. This is a deliberate commercial strategy to access the 85% of lymphoma patients treated in community clinics, not the major academic centers required for existing, more toxic CAR-T therapies.

While scientifically novel, the primary advantage of in vivo CAR-T therapy is its potential to overcome the significant logistical barriers of traditional CAR-T. By simplifying the process to a single injection, it could democratize access for patients far from specialized academic medical centers.

Scaling manufacturing and commercialization for an autologous CAR-T therapy like Carvykti is too complex for a small biotech alone. Legend Biotech's partnership with J&J was critical, combining Legend's science with J&J's global manufacturing, clinical development, and commercial muscle.

Unlike traditional pharmaceuticals, cell therapies are patient-specific (one batch, one patient). This makes the centralized global manufacturing model inefficient. A decentralized, local production network is essential for global accessibility and scalability, fundamentally changing the supply chain strategy.

Bispecific antibodies are "off-the-shelf" therapies with manageable side effects that don't require specialized manufacturing centers like CAR T. This allows community practices to administer highly effective T-cell redirecting therapies, equalizing access for patients far from major academic institutions.

Contrary to the belief that CAR-T therapies require inpatient hospitalization, about 50% of Carvykti infusions occur in an outpatient setting. This flexibility allows more hospitals to offer the treatment and makes it more accessible for patients, revolutionizing the delivery model for complex cell therapies.

To solve patient enrollment bottlenecks, biotech companies should directly support and utilize community-based medical centers where 95% of patients receive care. These local clinics are a more accessible and efficient alternative to large, bureaucratic academic institutions.

The ideal future for personalized cell therapies involves decentralized manufacturing using mobile units at the point of care, like a hospital. This model, which Cellino is pioneering with Mass General Hospital, eliminates complex logistics, reduces costs, and broadens patient access beyond major urban centers to rural areas.

Unlike complex cell therapies requiring hospital stays, Diakonos' treatment is a quick outpatient injection. This simplified administration allows them to partner with community cancer centers, not just major research hospitals, dramatically increasing trial recruitment speed and potential market access.